<DOC>
	<DOCNO>NCT01425281</DOCNO>
	<brief_summary>Prospective , randomize ( 2:1 ) , active control , single blind , parallel two-arm , multi-center clinical investigation use Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System ( ABSORB BVS ) ; compare Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System ( XIENCE )</brief_summary>
	<brief_title>ABSORB II Randomized Controlled Trial</brief_title>
	<detailed_description>In USA , ABSORB BVS currently development Abbott Vascular . Not available sale US .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>General Inclusion Criteria Subject must least 18 year age less 85 year age . Subject must agree participate clinical investigation period three year follow index procedure . This include clinical trial medication invasive procedure . Questionnairebased study , study noninvasive require medication allow . Subject able verbally confirm understand risk , benefit treatment alternative receive ABSORB BVS system he/she his/her legally authorized representative provide write informed consent prior Clinical Investigation related procedure , approve appropriate Ethics Committee . Subject must evidence myocardial ischemia ( e.g. , stable unstable angina , silent ischemia ) . Subject must acceptable candidate coronary artery bypass graft ( CABG ) surgery Subject must agree undergo clinical investigation planrequired followup visit , exercise testing , blood draw well adherence European Society Cardiology Guidelines completion quality life questionnaire subject diary collect information include limited tobacco usage , food intake , daily exercise body weight Angiographic Inclusion Criteria One two de novo native lesion locate different epicardial vessel . If two treatable lesion meet eligibility criterion , must separate major epicardial vessel ( leave anterior descend ( LAD ) septal diagonal branch , leave circumflex artery ( LCX ) obtuse marginal and/or ramus intermedius branch right coronary artery ( RCA ) branch ) . Lesion ( ) must visually estimate diameter stenosis ≥50 % &lt; 100 % TIMI flow ≥1 . Lesion ( ) must locate native coronary artery Dmax online QCA ≥2.25 mm ≤3.8 mm . Lesion ( ) must locate native coronary artery lesion ( ) length online QCA ≤48 mm . Percutaneous intervention lesion nontarget vessel allow do ≥30 day prior plan do 2 year index procedure . Percutaneous intervention lesion target vessel allow do &gt; 6 month prior plan do 2 year index procedure . Known hypersensitivity contraindication aspirin , heparin bivalirudin , antiplatelet medication specify use study ( clopidogrel prasugrel ticlopidine , inclusive ) , everolimus , poly ( Llactide ) , poly ( DLlactide ) , cobalt , chromium , nickel , tungsten , acrylic fluoro polymer contrast sensitivity adequately premedicated . Subject know diagnosis acute myocardial infarction ( AMI ) time precede index procedure relevant cardiac enzyme ( accord local standard hospital practice ) return within normal limit time procedure . Evidence ongoing acute myocardial infarction ECG prior procedure Subject current unstable arrhythmia . Left ventricular ejection fraction ( LVEF ) &lt; 30 % . Subject receive heart transplant organ transplant wait list organ transplant . Subject receive schedule receive chemotherapy malignancy within 30 day prior procedure . Subject receive immunosuppressant therapy and/or know immunosuppressive autoimmune disease ( e.g . human immunodeficiency virus , systemic lupus erythematosus , rheumatoid arthritis , severe asthma require immunosuppressive medication , etc. ) . Subject receive chronic anticoagulation therapy stop restart accord local hospital standard procedure . Elective surgery plan within 2 year procedure require discontinue either aspirin , clopidogrel , prasugrel ticlopidine . Subject platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , white blood cell count &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence hepatitis ) Known renal insufficiency ( e.g. , estimate glomerular filtration rate &lt; 60 ml/kg/1.73m² serum creatinine level &gt; 2.5 mg/dL , subject dialysis ) . History bleed diathesis coagulopathy refuse blood transfusion . Subject cerebrovascular accident ( CVA ) transient ischemic neurological attack ( TIA ) within past 6 month . Pregnant nursing subject plan pregnancy period 3 year follow index procedure . ( Female subject childbearing potential must negative pregnancy test do within 28 day prior index procedure contraception must use participation trial ) Other medical illness ( e.g. , cancer congestive heart failure ) know history substance abuse ( alcohol , cocaine , heroin etc . ) per physician judgment may cause noncompliance protocol confound data interpretation associate limited life expectancy . Subject already participate another clinical investigation yet reach primary endpoint . Subject belong vulnerable population ( per investigator 's judgment , e.g. , subordinate hospital staff sponsor staff ) subject unable read write . Angiographic Exclusion Criteria Target lesion prevents adequate ( residual stenosis target lesion ( ) ≤ 40 % visual assessment ) coronary predilatation . Target lesion leave main trunk . Aortoostial target lesion ( within 3 mm aorta junction ) . Target lesion locate within 2 mm origin LAD LCX . Target lesion locate distal diseased ( vessel irregularity per angiogram &gt; 20 % stenosed lesion ) arterial saphenous vein graft . Target lesion involve bifurcation lesion side branch ≥2 mm diameter , side branch &lt; 2mm diameter require guide wire protection dilatation . Total occlusion ( TIMI flow 0 ) , prior wire cross Excessive tortuosity ( ≥ two 45° angle ) , extreme angulation ( ≥90 ° ) proximal within target lesion . Restenotic previous intervention Heavy calcification proximal within target lesion . Target lesion involve myocardial bridge . Target vessel contain thrombus indicated angiographic image . Additionally clinically significant lesion ( ) ( ≥ 40 % diameter stenosis visual assessment ) percutaneous coronary intervention may require &lt; 2 year index procedure . Subject receive brachytherapy epicardial vessel ( include side branch ) Subject high probability procedure predilatation study device implantation ( necessary ) postdilatation require time index procedure treatment target vessel ( e.g . atherectomy , cut balloon )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Bioabsorbable</keyword>
	<keyword>Coronary scaffold</keyword>
	<keyword>Coronary Stent</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Total coronary occlusion</keyword>
	<keyword>Coronary artery restenosis</keyword>
	<keyword>Stent thrombosis</keyword>
	<keyword>Myocardial ischemia</keyword>
	<keyword>Coronary artery stenosis</keyword>
</DOC>